Clinical issues in inhibitors.
Anamestic inhibitors represent the major complication of haemophilia therapy now that clotting factor concentrates are virtually free of pathogen-transmission risk. Conventional clotting factor replacement is usually insufficient to prevent or treat bleeding in a haemophilia patient with a high responding inhibitor so that alternative treatment with bypassing agents is required. Despite their relative efficacy, their use does not achieve the same invariable haemostasis that patients without inhibitors do following treatment with factor concentrate replacement. This has led to the attempt to eradicate such inhibitors with immune tolerance induction. Success is not invariable, however, and many patients with long-term persistent high-titre inhibitors continue to experience great morbidity. Recently, this has given rise on a limited basis to attempts to use bypassing agents in prophylaxis regimens in an effort to alleviate this extreme morbidity. Each of these strategies is discussed in the context of their relative benefits and risks.
Astermark
J
J
Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmö, Sweden.
Santagostino
E
E
Keith Hoots
W
W
D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D006487:Hemostasis / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance
D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005169:Factor VIII